Karen Abbott, PhDUniversity of Georgia Targeting Tumor-Specific Glycosylation: Discovery of Novel Membrane Receptors Dr. Abbott’s work is focused on discovering new tumor-specific targets on the surface of cancer cells. Tumor-targeted therapy regimens will have less toxic side effects to normal tissues, and lead to a better quality of life for patients. This project is based […]
Read More
Shelley Hooks, PhDUniversity of Georgia A One-Two Punch: Dual Mechanisms for RGS inhibition of cell survival signals Acquired chemoresistance, in which patients whose tumors initially respond to cisplatin ultimately relapse with drug-resistant disease, is a major factor in the low survival rate among ovarian cancer patients. To address this clinical problem, it is absolutely necessary […]
Read MoreStarting April 1, 2025, the Rivkin Center’s ovarian cancer research funding, global symposium and fundraising activities will continue under the leadership of Ovarian Cancer Research Alliance (OCRA).
